Updates in head and neck cancers

KEYNOTE022: Triplet therapy for BRAF melanoma

First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

ESMO 2018: Melanoma highlights

IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy

KEYNOTE048: First line pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

ESMO 2018: Highlights

IMpassion 130 trial results: Immunotherapy for metastatic breast cancer

The TRIBE-2 study for colorectal cancer

Advances in metastatic non small cell lung cancer

Comment on the JAVELIN study: RCC immunotherapy

Use of T-VEC in early metastatic melanoma